The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Women’s football in Moray can develop even further thanks to the creation of a pathway partnership. Elgin City women’s team, ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...
The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...
The FDA’s Breakthrough Devices Program is designed to accelerate development and review of devices that offer meaningful advances in care for serious or life-threatening conditions. With more than ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...
INDIANAPOLIS – In a unanimous vote, the Indiana House of Representatives passed House Bill 1277, a piece of legislation aimed at overhauling the state’s embattled PathWays for Aging Medicaid program.
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...